-+ 0.00%
-+ 0.00%
-+ 0.00%

GRAIL (GRAL) Posts Fresh Results, Is The Stock Fully Priced?

Simply Wall St·11/15/2026 16:18:17
Listen to the news

GRAIL (GRAL) released third quarter and nine month results on November 4, 2026, giving investors fresh detail on sales momentum, revenue trends, and ongoing losses from continuing operations.

The stock has cooled in the very short term, with a 1 day share price return of down 4.5% and a 7 day share price return of down 4.6%. However, the 90 day share price return of 65.7% and 1 year total shareholder return of 45.5% indicate momentum that has been building into these latest GRAIL results.

Look beyond GRAIL's volatile quarter and see how other health-focused companies with stronger balance sheets and fundamentals compare with the curated list of solid balance sheet and fundamentals (24 results)

Bulls see GRAIL’s recent 90 day surge and rising sales as proof the story is intact. Bears point to ongoing heavy losses and volatility. Which side do the current valuation numbers lean toward next?

Most Popular Narrative: 12% Undervalued

GRAIL closed at $115.89, while the analyst consensus Narrative on Simply Wall St points to a fair value of $132.11 and applies a 7.5% discount rate to its long term cash flows and earnings power.

The $110 million equity financing and commercialization collaboration with Samsung, along with GRAIL’s cash position of $788.7 million and runway into 2029, provides resources to scale operations and international distribution. This is likely to affect future earnings and cash burn.

See why 20 investors see GRAIL as 12% undervalued.

Result: Fair Value of $132.11 (UNDERVALUED)

Still, the GRAIL story could be tested if high quarterly losses persist or if future clinical and regulatory decisions limit reimbursement and test volumes.

Find out about the key risks to this GRAIL narrative.

Another View: What GRAIL’s Price-To-Sales Says

The SWS DCF model points to a future cash flow value of $21.94 per share, well below GRAIL’s current $115.89 price. By that lens, the stock screens as expensive and raises the question of whether the multi cancer testing story is already more than fully priced in.

For readers who want to see how this cash flow view is built step by step, Look into how the SWS DCF model arrives at its fair value.

GRAL Discounted Cash Flow as at Nov 2026
GRAL Discounted Cash Flow as at Nov 2026

Next Steps

Mixed messages on GRAIL so far. If the balance between risks and rewards feels tight, consider acting quickly and review the data for yourself with 2 key rewards and 5 important warning signs.

Looking for more investment ideas beyond GRAIL?

If GRAIL has sharpened your thinking, now is the moment to widen your watchlist with a few focused stock ideas tailored to different priorities.